FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095081231> ?p ?o ?g. }

• W3095081231 endingPage "88" @default.
• W3095081231 startingPage "76" @default.
• W3095081231 abstract "Background: Triple-negative breast cancer (TNBC) is a great threat to global women's health due to its high metastatic potential. Epithelial-to-mesenchymal transition (EMT) is considered as a key event in the process of metastasis. So the pharmacological targeting of EMT might be a promising strategy in improving the therapeutic efficacy of TNBC. Here, we investigated the effect of shikonin exerting on EMT and consequently the metastasis of TNBC cells and its underlying mechanism. Methods: The invasive and migratory capacities of MDA-MB-231 and BT549 cells were tested using transwell invasion and wound healing assay. MiR-17-5p expression was examined by qRT-PCR. MiR-17-5p targeted genes were predicted with different bioinformatic algorithms from four databases (TargetScan, miRanda, PITA and picTar) and further screened by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The differential expressions of predicted genes and their correlations with miR-17-5p were identified in breast cancer patients based on The Cancer Genome Atlas (TCGA) database. The interaction between phosphatase and tensin homolog deleted on chromosome ten (PTEN) and miR-17-5p was analyzed by luciferase reporter assay. The overexpression vector and small interfering RNA were constructed to investigate the role PTEN played in metastasis and EMT regulation. The expressions of EMT markers, protein kinase B (Akt) and phospho-Akt (p-Akt) were evaluated by western blot. Results: Shikonin suppressed the migration and invasion of MDA-MB-231 and BT549 cells and meanwhile the corresponding alterations of EMT biomarkers were observed in shikonin treated MDA-MB-231 cells. Shikonin inhibited the expression of miR-17-5p, which was upregulated in breast cancer. The 3'-untranslated region (3'-UTR) of PTEN was found to be direct binding target of miR-17-5p by luciferase reporter assays. PTEN functioned as a suppressor both in the metastasis and EMT of TNBC cells. Moreover, Akt and p-Akt (Ser473) were involved in the process of inhibition in cancer cell migration, invasion and EMT by shikonin. Conclusions: Shikonin inhibits migration and invasion of TNBC cells by suppressing EMT via miR-17-5p/PTEN/Akt pathway. This suggests shikonin as a promising therapeutic agent to counteract metastasis in the TNBC patients." @default.
• W3095081231 created "2020-11-09" @default.
• W3095081231 creator A5024460760 @default.
• W3095081231 creator A5026780331 @default.
• W3095081231 creator A5039899259 @default.
• W3095081231 creator A5057754385 @default.
• W3095081231 creator A5070413989 @default.
• W3095081231 creator A5070644920 @default.
• W3095081231 creator A5073896710 @default.
• W3095081231 creator A5076036593 @default.
• W3095081231 creator A5085042209 @default.
• W3095081231 date "2021-01-01" @default.
• W3095081231 modified "2023-10-14" @default.
• W3095081231 title "Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via miR-17-5p/PTEN/Akt pathway" @default.
• W3095081231 cites W1983289899 @default.
• W3095081231 cites W1983848182 @default.
• W3095081231 cites W1989854110 @default.
• W3095081231 cites W1992244344 @default.
• W3095081231 cites W2002925764 @default.
• W3095081231 cites W2021543366 @default.
• W3095081231 cites W2023694015 @default.
• W3095081231 cites W2033043455 @default.
• W3095081231 cites W2035618305 @default.
• W3095081231 cites W2036422868 @default.
• W3095081231 cites W2047146433 @default.
• W3095081231 cites W2058252240 @default.
• W3095081231 cites W2080174827 @default.
• W3095081231 cites W2081024827 @default.
• W3095081231 cites W2093472132 @default.
• W3095081231 cites W2114104545 @default.
• W3095081231 cites W2300347061 @default.
• W3095081231 cites W2328277364 @default.
• W3095081231 cites W2431996803 @default.
• W3095081231 cites W2570618306 @default.
• W3095081231 cites W2599446324 @default.
• W3095081231 cites W2613740940 @default.
• W3095081231 cites W2738140292 @default.
• W3095081231 cites W2743491871 @default.
• W3095081231 cites W2807261444 @default.
• W3095081231 cites W2809133542 @default.
• W3095081231 cites W2890607116 @default.
• W3095081231 cites W2909474213 @default.
• W3095081231 cites W2911725508 @default.
• W3095081231 cites W2921533346 @default.
• W3095081231 cites W2938987972 @default.
• W3095081231 cites W2943843209 @default.
• W3095081231 cites W2944376069 @default.
• W3095081231 cites W2953778893 @default.
• W3095081231 cites W2966296683 @default.
• W3095081231 cites W2967026559 @default.
• W3095081231 cites W2973628697 @default.
• W3095081231 cites W2974784329 @default.
• W3095081231 cites W2989690384 @default.
• W3095081231 cites W2989953430 @default.
• W3095081231 cites W2995652422 @default.
• W3095081231 cites W2999087022 @default.
• W3095081231 cites W3003807413 @default.
• W3095081231 cites W3005104384 @default.
• W3095081231 cites W3033869790 @default.
• W3095081231 cites W3038005961 @default.
• W3095081231 cites W336942160 @default.
• W3095081231 doi "https://doi.org/10.7150/jca.47553" @default.
• W3095081231 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7738816" @default.
• W3095081231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33391404" @default.
• W3095081231 hasPublicationYear "2021" @default.
• W3095081231 type Work @default.
• W3095081231 sameAs 3095081231 @default.
• W3095081231 citedByCount "30" @default.
• W3095081231 countsByYear W30950812312021 @default.
• W3095081231 countsByYear W30950812312022 @default.
• W3095081231 countsByYear W30950812312023 @default.
• W3095081231 crossrefType "journal-article" @default.
• W3095081231 hasAuthorship W3095081231A5024460760 @default.
• W3095081231 hasAuthorship W3095081231A5026780331 @default.
• W3095081231 hasAuthorship W3095081231A5039899259 @default.
• W3095081231 hasAuthorship W3095081231A5057754385 @default.
• W3095081231 hasAuthorship W3095081231A5070413989 @default.
• W3095081231 hasAuthorship W3095081231A5070644920 @default.
• W3095081231 hasAuthorship W3095081231A5073896710 @default.
• W3095081231 hasAuthorship W3095081231A5076036593 @default.
• W3095081231 hasAuthorship W3095081231A5085042209 @default.
• W3095081231 hasBestOaLocation W30950812311 @default.
• W3095081231 hasConcept C104317684 @default.
• W3095081231 hasConcept C121608353 @default.
• W3095081231 hasConcept C126322002 @default.
• W3095081231 hasConcept C185592680 @default.
• W3095081231 hasConcept C190283241 @default.
• W3095081231 hasConcept C194232998 @default.
• W3095081231 hasConcept C2777609662 @default.
• W3095081231 hasConcept C2780110267 @default.
• W3095081231 hasConcept C502942594 @default.
• W3095081231 hasConcept C530470458 @default.
• W3095081231 hasConcept C55493867 @default.
• W3095081231 hasConcept C71924100 @default.
• W3095081231 hasConcept C75217442 @default.
• W3095081231 hasConcept C76419328 @default.
• W3095081231 hasConcept C86554907 @default.
• W3095081231 hasConceptScore W3095081231C104317684 @default.

• next